The Germany Nuclear Imaging Market size is estimated at USD 504.08 million in 2024, and is expected to reach USD 614.17 million by 2029, growing at a CAGR of 4.03% during the forecast period (2024-2029).
COVID-19 has severely impacted the market studied during the year 2020 owing to quick actions taken by the government for postponing non-essential diagnostic procedures in hospitals. Besides the negative impact of COVID-19, it has created opportunities for players in the nuclear imaging field to establish their presence by launching new products or progressing clinical studies in this field. For instance, in April 2021, Isotopen Technologien Munchen, Germany received a USD 109 million loan to push forward the study of Lutetium-177 which is expected to emit a low amount of radioactive energy as compared to other radiopharmaceuticals. Owing to such activities in the country, the nuclear imaging market is getting the benefits and is expected to witness strong growth in the coming years.
Factors such as the increasing burden of chronic diseases and the presence of key companies in the country are responsible for the market growth. Furthermore, many companies entered into a partnership to provide the radiopharmaceutical industry with a unique service solution for theranostic drug development. For instance, in July 2021, Oncodesign, Covalab, CheMatech, and ABX-CRO entered into a partnership to launch DRIVE-MRT (Molecular Radiotherapy) solution, which will have all technologies related to the validation of targets, the generation and optimization of vectors and the radiochemistry and PET / SPECT imaging techniques. These partnerships are streghthning the market of nuclear imaging in Germany.
Hence, due to the above-mentioned factors, the market for nuclear imaging is growing rapidly in Germany.
According to the 2020 Globocan report, there were 274,364 new cancer cases diagnosed and 86,684 deaths due to cancer in 2020. Adding to that, the number of prevalent cases (5 years) of cancer was 2,188,176. The most common cancers in Germany are lung cancer, prostate cancer, bladder cancer, colorectum cancer, and skin cancer. Similarly, as per the Robert Koch Institute, 2021 data, approximately 16,500 patients develop kidney cancer in Germany each year. The rising cases of cancer in the country are augmenting the demand for better diagnosis in the early stages of the disease. As nuclear imaging is one of the most reliable diagnostic methods for cancers, it is believed that the market for nuclear imaging will witness strong growth over the forecast period.
Furthermore, data published by the University Hospital of Würzburg, Germany in 2021 suggests that FDG PET/CT imaging had a high negative predictive value in detecting cervical lymph node metastasis in patients with newly diagnosed, treatment-naive Squamous Cell carcinoma of the oral cavity. The scans can also detect metastasis proving the multiple uses of these tests. Hence, the effectiveness of PET CT scan in the diagnosis of certain cancers is augmenting its demand across the country.
This product will be delivered within 2 business days.
COVID-19 has severely impacted the market studied during the year 2020 owing to quick actions taken by the government for postponing non-essential diagnostic procedures in hospitals. Besides the negative impact of COVID-19, it has created opportunities for players in the nuclear imaging field to establish their presence by launching new products or progressing clinical studies in this field. For instance, in April 2021, Isotopen Technologien Munchen, Germany received a USD 109 million loan to push forward the study of Lutetium-177 which is expected to emit a low amount of radioactive energy as compared to other radiopharmaceuticals. Owing to such activities in the country, the nuclear imaging market is getting the benefits and is expected to witness strong growth in the coming years.
Factors such as the increasing burden of chronic diseases and the presence of key companies in the country are responsible for the market growth. Furthermore, many companies entered into a partnership to provide the radiopharmaceutical industry with a unique service solution for theranostic drug development. For instance, in July 2021, Oncodesign, Covalab, CheMatech, and ABX-CRO entered into a partnership to launch DRIVE-MRT (Molecular Radiotherapy) solution, which will have all technologies related to the validation of targets, the generation and optimization of vectors and the radiochemistry and PET / SPECT imaging techniques. These partnerships are streghthning the market of nuclear imaging in Germany.
Hence, due to the above-mentioned factors, the market for nuclear imaging is growing rapidly in Germany.
Germany Nuclear Imaging Market Trends
Oncology is Expected to Witness Significant Share in Application Segment
Cancer is one of the leading causes of morbidity and mortality in Germany. The burden of cancer is rising every year as more people are being diagnosed with cancer in the country.According to the 2020 Globocan report, there were 274,364 new cancer cases diagnosed and 86,684 deaths due to cancer in 2020. Adding to that, the number of prevalent cases (5 years) of cancer was 2,188,176. The most common cancers in Germany are lung cancer, prostate cancer, bladder cancer, colorectum cancer, and skin cancer. Similarly, as per the Robert Koch Institute, 2021 data, approximately 16,500 patients develop kidney cancer in Germany each year. The rising cases of cancer in the country are augmenting the demand for better diagnosis in the early stages of the disease. As nuclear imaging is one of the most reliable diagnostic methods for cancers, it is believed that the market for nuclear imaging will witness strong growth over the forecast period.
Furthermore, data published by the University Hospital of Würzburg, Germany in 2021 suggests that FDG PET/CT imaging had a high negative predictive value in detecting cervical lymph node metastasis in patients with newly diagnosed, treatment-naive Squamous Cell carcinoma of the oral cavity. The scans can also detect metastasis proving the multiple uses of these tests. Hence, the effectiveness of PET CT scan in the diagnosis of certain cancers is augmenting its demand across the country.
Germany Nuclear Imaging Industry Overview
The nuclear imaging market is highly competitive and consists of a few major players. In terms of market share, few of the major players currently dominate the market. Companies, like Bracco Imaging SpA, Curium, Cardinal Health Inc., Koninklijke Philips NV, GE Healthcare, and Siemens Healthineers, among others, hold the substantial share in the market.Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION
6 COMPETITIVE LANDSCAPE
Methodology
LOADING...
